N. Nanko, M. Tanikawa, M. Mase, et al., “Involvement of Hypoxia-Inducible Factor-1alpha and Vascular Endothelial Growth Factor in the Mechanism of Development of Chronic Subdural Hematoma,” Neurologia Medico- Chirurgica (Tokyo), Vol. 49, No. 9, 2009, pp. 379-385. doi:10.2176/nmc.49.379

has been cited by the following article:

• TITLE: Resolution of Chronic Subdural Hematoma after Treatment with Tumor Necrosis Factor Alpha Inhibitor

  AUTHORS: Donald Ross

  KEYWORDS: Chronic Subdural Hematoma, Tumor Necrosis Factor Alpha, Inflammation

  JOURNAL NAME: Neuroscience and Medicine, Vol.2 No.4, December 2, 2011

  ABSTRACT: Background and Importance: Chronic subdural hematomas (cSDH) are a common problem for which solutions remain imperfect. Surgery is effective, but not without risk. Recent data have suggested a role for inflammation in the genesis of cSDH and several reports have documented some benefit to steroid treatment. In this report, a possible role for tumor necrosis factor alpha blockade in the resolution of a multiply recurrent cSDH is described. Clinical Presentation: An 86-year-old man with rheumatoid arthritis treated with infliximab presented with a large, symptomatic, multiloculated cSDH. Infliximab was withheld and craniotomy for evacuation was uncomplicated, but recurrent symptoms were noted and a recurrence was operated upon again several weeks later. Follow up CT showed a second recurrence. The patient requested to go back on his infliximab due to painful arthralgias. After a single dose of 10 mg/kg, follow up CT showed that the cSDH resolved and did not recur. Conclusion: Anti-TNF-alpha treatment with infliximab may have played a role in the resolution of this patient’s cSDH. Further investigation of this possible effect seems warranted.